TY - JOUR
T1 - Deferred radical prostatectomy in patients who initially elected for active surveillance
T2 - a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study
AU - Tohi, Yoichiro
AU - Kato, Takuma
AU - Nakamura, Masaki
AU - Matsumoto, Ryuji
AU - Sasaki, Hiroshi
AU - Mitsuzuka, Koji
AU - Inokuchi, Junichi
AU - Hashine, Katsuyoshi
AU - Yokomizo, Akira
AU - Naito, Hirohito
AU - Hara, Isao
AU - Kawamura, Norihiko
AU - Inoue, Masaharu
AU - Fukuhara, Hiroshi
AU - Maruyama, Satoru
AU - Sakamoto, Shinichi
AU - Saito, Toshihiro
AU - Egawa, Shin
AU - Kakehi, Yoshiyuki
AU - Sugimoto, Mikio
N1 - Funding Information:
We would like to thank Dr. Shintaro Narita, Dr. Wataru Obara, Dr. Mitsugu Kanehira, Dr. Kazuo Nishimura, Dr. Norio Nonomura, Dr. Motohide Uemura, Dr. Tadashi Matsuda, Dr. Hidefumi Kinoshita, Dr. Masatoshi Eto, Dr. Kenichi Tabata, Dr. Hideyasu Tsumura, Dr. Hiroshi Okuno, D.r Takayoshi Miura, Dr. Shusuke Akamatsu, Dr. Osamu Ukimura, Dr. Takumi Shiroishi, Dr. Naoki Ninomiya, Dr. Tomomi Kamba, Dr. Yoji Murakami, Dr. Yasuo Yamamoto, Dr. Tadashi Murata, Dr. Koji Inoue, Dr. Kazuhiro Suzuki, Dr. Yoshiyuki Miyazawa, Dr. Yukio Kageyama, Dr. Kohei Hashimoto, Dr. Naoya Masumori, Dr. Masafumi Matsumura, Dr. Ryotaro Tomida, Dr. Tomohiko Ichikawa, Dr. Nobuyoshi Takeuchi, Dr. Yukio Naya, Dr. Satoko Kojima, Dr. Akira Miyajima, Dr. Masahiro Nitta, Dr. Haruki Kume, Dr. Koichiro Akakura, Dr. Hiroyoshi Suzuki, Dr. Naoto Kamiya, Dr. Hiro-omi Kanayama, Dr. Yoshito Kusuhara, Dr. Kiyotaka Kawashima, Dr. Hideki Sakai, Dr. Tomoaki Hakariya, Dr. Toshiki Tanikawa, Dr. Yoshihiko Tomita, Dr. Takashi Kasahara, Dr. Takayuki Sugiyama, Dr. Hideaki Miyake, Dr. Kenichiro Shiga, Dr. Jun Teishima, Dr. Takeshi Ueno, Dr. Takashige Abe, Dr. Toshiyuki Kamoto, Dr. Naoki Terada, Dr. Norihiko Tsuchiya, Dr. Hidenori Kanno, Dr. Hiroaki Matsumoto, Dr. Seiichi Saito, Dr. Takashi Kimura, Dr. Hiromi Hirama, and PRIAS-JAPAN secretary Akiko Mori for their great contribution to this study.
Publisher Copyright:
© 2021, Japan Society of Clinical Oncology.
PY - 2022/1
Y1 - 2022/1
N2 - Background: This study aimed to evaluate the pathological findings and oncological outcomes of deferred radical prostatectomy in patients who initially elected for active surveillance in a Japanese cohort. Methods: We retrospectively analyzed data collected from a multi-institutional prospective observational cohort of the Prostate Cancer Research International: Active Surveillance-JAPAN study between January 2010 and September 2020. Triggers for radical prostatectomy were disease progression based on pathological findings of repeat biopsy and patients’ request. The primary end point was evaluation of prostate-specific antigen recurrence-free survival. Secondary end points were overall survival and comparison of pathological and oncological outcomes between patients stratified into immediate or late radical prostatectomy group by time to radical prostatectomy. Results: Overall, 162 patients (15.7%) with prostate cancer underwent initial active surveillance followed by radical prostatectomy. The median time to radical prostatectomy was 18 months (interquartile range 14–43.3), and the median postoperative follow-up was 32 months (interquartile range 14–57.5). Prostate-specific antigen recurrence was observed in eight patients (4.9%). The 3-year prostate-specific antigen recurrence-free survival rate was 96.9%. The 5-year overall survival rate was 100%; however, one patient died of another cause. There were no significant differences in pathological findings between immediate and late radical prostatectomy groups. No significant difference in prostate-specific antigen recurrence-free survival was found between the two groups (log-rank p = 0.34). Conclusions: Radical prostatectomy after active surveillance, as an initial treatment option, does not lead to loss of curative chances in Japanese patients with early-stage prostate cancer in the short follow-up period.
AB - Background: This study aimed to evaluate the pathological findings and oncological outcomes of deferred radical prostatectomy in patients who initially elected for active surveillance in a Japanese cohort. Methods: We retrospectively analyzed data collected from a multi-institutional prospective observational cohort of the Prostate Cancer Research International: Active Surveillance-JAPAN study between January 2010 and September 2020. Triggers for radical prostatectomy were disease progression based on pathological findings of repeat biopsy and patients’ request. The primary end point was evaluation of prostate-specific antigen recurrence-free survival. Secondary end points were overall survival and comparison of pathological and oncological outcomes between patients stratified into immediate or late radical prostatectomy group by time to radical prostatectomy. Results: Overall, 162 patients (15.7%) with prostate cancer underwent initial active surveillance followed by radical prostatectomy. The median time to radical prostatectomy was 18 months (interquartile range 14–43.3), and the median postoperative follow-up was 32 months (interquartile range 14–57.5). Prostate-specific antigen recurrence was observed in eight patients (4.9%). The 3-year prostate-specific antigen recurrence-free survival rate was 96.9%. The 5-year overall survival rate was 100%; however, one patient died of another cause. There were no significant differences in pathological findings between immediate and late radical prostatectomy groups. No significant difference in prostate-specific antigen recurrence-free survival was found between the two groups (log-rank p = 0.34). Conclusions: Radical prostatectomy after active surveillance, as an initial treatment option, does not lead to loss of curative chances in Japanese patients with early-stage prostate cancer in the short follow-up period.
UR - http://www.scopus.com/inward/record.url?scp=85116216485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116216485&partnerID=8YFLogxK
U2 - 10.1007/s10147-021-02041-4
DO - 10.1007/s10147-021-02041-4
M3 - Article
C2 - 34599725
AN - SCOPUS:85116216485
VL - 27
SP - 194
EP - 201
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 1
ER -